Answers are grounded in this paper and cite their sources.
Papillary thyroid carcinoma (PTC) represents the most common endocrine malignancy, and fine needle aspiration (FNA) cytology remains the cornerstone of its preoperative diagnosis. Recent management strategies for thyroid cancer require not only accurate diagnosis but also reliable prediction of tumor aggressiveness before surgery. Although FNA cytology is highly effective in identifying malignant lesions, its potential role in predicting aggressive clinicopathologic behavior remains an area of ongoing investigation. This narrative review evaluates the current evidence regarding cytological predictors of aggressiveness in papillary thyroid carcinoma and explores their correlation with key clinicopathologic parameters. In addition, the review examines the emerging role of molecular testing and integrative cytomolecular approaches in enhancing the prognostic value of FNA cytology to improve preoperative risk stratification and guide individualized treatment planning. A literature review was conducted focusing on cytological features associated with aggressive behavior in PTC, correlations between FNA cytomorphology and clinicopathologic outcomes, and molecular alterations detectable in cytological specimens. Recent advances in molecular diagnostics, next-generation sequencing, artificial intelligence–assisted cytology, and imaging-based predictive models were also reviewed. Accumulating evidence suggests that several cytomorphological features observed in FNA specimens may be associated with aggressive biological behavior in PTC. Increased cellularity, marked nuclear pleomorphism, complex three-dimensional architectural patterns, necrotic background, and the presence of psammoma bodies have been reported to correlate with adverse clinicopathologic parameters, including lymph node metastasis and extrathyroidal extension. In addition, certain cytological patterns may reflect underlying molecular alterations that influence tumor progression. The integration of molecular markers, particularly BRAF V600E and TERT promoter mutations, with cytological assessment has demonstrated improved prognostic accuracy. Emerging technologies, including digital pathology, artificial intelligence–based image analysis, and radiomics, are also showing promising potential for improving preoperative risk assessment. FNA cytology remains an essential diagnostic tool in the evaluation of PTC, and cytomorphological features may provide important clues regarding tumor aggressiveness. However, cytology alone cannot fully capture the biological complexity of PTC. Integrating cytological evaluation with molecular diagnostics and advanced analytical technologies may enhance preoperative risk stratification and support more precise, individualized management strategies for patient management.
No takes yet. Share an insight, caveat, or question.
Soltani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: